| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CCKB-type receptors (CCK2 receptors). Cholecystokinin (26-33) free acid is a highly selective ligand for CCKB-type receptors found in the vertebrate CNS. CCK receptors are G protein-coupled receptors involved in the regulation of food intake, satiety, and gastrointestinal function. By binding to CCK2 receptors, the compound reduces food intake and stimulates gallbladder contraction. It also induces a mild taste aversion conditioned reflex in rats.
|
|---|---|
| ln Vitro |
Cholecystokinin (26-33) free acid reduces food intake and stimulates gallbladder contraction. As a highly selective ligand for CCKB-type receptors, it activates CCK2 receptor signaling in the CNS. The compound induces a mild taste aversion conditioned reflex in rats. Its in vitro activity includes receptor binding and activation of downstream signaling pathways in neuronal cells.
|
| ln Vivo |
In vivo, cholecystokinin (26-33) free acid reduces food intake and stimulates gallbladder contraction. It induces a mild taste aversion conditioned reflex in rats. The compound’s effects on feeding behavior and gastrointestinal function make it a valuable tool for studying the role of CCK in metabolic regulation and satiety signaling. It is used in neurobiology and metabolic research.
|
| Enzyme Assay |
Non-cell-based assays for cholecystokinin (26-33) free acid include receptor binding assays using radiolabeled CCK or CCK analogs. The compound’s affinity for CCK2 receptors is determined by competitive displacement of labeled ligand. Receptor activation can be assessed using GTPγS binding assays or second messenger assays. Standard analytical methods including HPLC and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for cholecystokinin (26-33) free acid use cells expressing CCK2 receptors (e.g., neuronal cell lines, transfected cells). Receptor activation is assessed by measuring intracellular calcium mobilization or cAMP modulation. The compound’s effects on neuronal excitability and neurotransmitter release can be studied in primary neuronal cultures. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo studies of cholecystokinin (26-33) free acid are conducted in rodent models to assess its effects on food intake, gallbladder contraction, and taste aversion. The compound is administered via intracerebroventricular (ICV) or peripheral injection. Food intake is measured over time, gallbladder contraction is assessed by ultrasound or bile collection, and taste aversion is evaluated using conditioned taste aversion paradigms.
|
| ADME/Pharmacokinetics |
Cholecystokinin (26-33) free acid is a peptide with the sequence DYMGWMDF. It is a fragment of cholecystokinin (CCK). The compound is a highly selective ligand for CCKB-type receptors (CCK2 receptors). Purity is ≥99.8%. It should be stored under recommended conditions for peptide storage. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for cholecystokinin (26-33) free acid are limited. As a peptide fragment of the endogenous hormone CCK, it is generally considered to have low toxicity at physiological concentrations. The compound is intended for research use only and is not for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound.
|
| References |
[1]. Tachibana T, et, al. Feeding-suppressive mechanism of sulfated cholecystokinin (26-33) in chicks. Comp Biochem Physiol A Mol Integr Physiol. 2012 Apr;161(4):372-8.
|
| Additional Infomation |
Cholecystokinin (26-33) free acid (CCK-8 free acid) is a peptide fragment of cholecystokinin (CCK) with the sequence DYMGWMDF. It is a highly selective ligand for CCKB-type receptors (CCK2 receptors) found in the vertebrate CNS. The compound reduces food intake and stimulates gallbladder contraction. It induces a mild taste aversion conditioned reflex in rats. It is used as a research tool for neurobiology and metabolic research and is for research use only.
|
| Molecular Formula |
C49H61N9O14S2
|
|---|---|
| Molecular Weight |
1064.19
|
| Exact Mass |
1063.377
|
| CAS # |
103974-46-5
|
| PubChem CID |
9833257
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1545.8±65.0 °C at 760 mmHg
|
| Flash Point |
888.7±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
3.53
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
31
|
| Heavy Atom Count |
74
|
| Complexity |
1920
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
S(C)CC[C@@H](C(N[C@H](C(N[C@H](C(=O)O)CC1C=CC=CC=1)=O)CC(=O)O)=O)NC([C@H](CC1=CNC2C=CC=CC1=2)NC(CNC([C@H](CCSC)NC([C@H](CC1C=CC(=CC=1)O)NC([C@H](CC(=O)O)N)=O)=O)=O)=O)=O
|
| InChi Key |
PUZFEBZBSNCBNS-YRVFCXMDSA-N
|
| InChi Code |
InChI=1S/C49H61N9O14S2/c1-73-18-16-34(54-46(68)36(20-28-12-14-30(59)15-13-28)56-43(65)32(50)23-41(61)62)44(66)52-26-40(60)53-37(22-29-25-51-33-11-7-6-10-31(29)33)47(69)55-35(17-19-74-2)45(67)57-38(24-42(63)64)48(70)58-39(49(71)72)21-27-8-4-3-5-9-27/h3-15,25,32,34-39,51,59H,16-24,26,50H2,1-2H3,(H,52,66)(H,53,60)(H,54,68)(H,55,69)(H,56,65)(H,57,67)(H,58,70)(H,61,62)(H,63,64)(H,71,72)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
|
| Chemical Name |
(3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (93.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9397 mL | 4.6984 mL | 9.3968 mL | |
| 5 mM | 0.1879 mL | 0.9397 mL | 1.8794 mL | |
| 10 mM | 0.0940 mL | 0.4698 mL | 0.9397 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
